Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Sartorius snags Essen for $320M
April 2017
SHARING OPTIONS:

ANN ARBOR, Mich.—Essen BioScience Inc., which is owned by the specialized private equity firm SFW Capital Partners, has agreed to be acquired by Sartorius for $320 million in cash. The transaction is expected to close at the end of the first quarter, pending antitrust clearance. This deal will expand Sartorius' portfolio for bioanalytics, and Essen is forecast to see sales revenues of roughly $60 million this year. Essen develops instrumentation, software and reagents for real-time live-cell analysis to aid in accelerating drug discovery and development.
 
“With the Essen real-time, live-cell analysis platform, we will add another key technology for advancing and accelerating drug discovery applications to our lab divisions’ portfolio,” said Sartorius CEO Joachim Kreuzburg. “This powerful technology offers important synergies with our IntelliCyt business. Going forward, Sartorius will be able to provide our customers the broadest and, we believe, the most innovative portfolio for cell analysis in the industry.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.